Skip to content

Evaluation of LB in THA

Evaluation of Intraoperative, Local Site Injections of Liposomal Bupivacaine as an Alternative to Standard Local Anesthetics in Patients Undergoing Total Hip Arthroplasty

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03341104
Enrollment
173
Registered
2017-11-14
Start date
2013-01-01
Completion date
2016-07-30
Last updated
2017-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Disease

Brief summary

This study aims to compare the effectiveness of liposomal bupivacaine (LB) versus standard of practice local injection containing plain bupivacaine.

Detailed description

Investigation of liposomal bupivacaine to determine if this drug is a valid alternative to standard of care local anesthesia based on evaluation in total hip arthroplasty This is a retrospective cohort study of consecutive patients undergoing THA at 3 hospitals within a U.S. healthcare system from January 2013 to July 2016. The control group received the standard of care undergoing THA (plain bupivacaine or ropivacaine), while the LB group received a mixture containing this drug as the alternative to the standard care. The outcome variables include hospital length of stay, readmissions, total hospital costs, patient pain scores, discharge disposition, morphine equivalent opioid consumption, and postoperative patient ambulation. Generalized linear models were employed to examine aforementioned outcomes controlling for age, gender, race, BMI, alcohol use, tobacco use, and surgeons..

Interventions

Replace bupivacaine with bupivacaine liposome

Sponsors

University of Illinois College of Medicine at Peoria
CollaboratorOTHER
OSF Healthcare System
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males or females over the age of 18 * have undergone a THA surgery during the period of interest January 2013 to July 2016).

Exclusion criteria

* excluded from the study based on the following criteria: 1. Concurrent, painful, physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical treatment; 2. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder; and 3. Significant renal or hepatic insufficiency.

Design outcomes

Primary

MeasureTime frameDescription
Comparing physical function of the control group with the experimental group43 monthsdistance in feet walked
Comparing length of stay in acute care facility of the control group with the experimental group43 monthsnumber of days
Comparing total hospital costs of the control group with the experimental group43 monthsNumber of dollars

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026